<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6316">
  <stage>Registered</stage>
  <submitdate>7/02/2017</submitdate>
  <approvaldate>7/02/2017</approvaldate>
  <nctid>NCT03053440</nctid>
  <trial_identification>
    <studytitle>A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)</studytitle>
    <scientifictitle>A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BGB-3111-302</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Waldenström's Macroglobulinemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BGB-3111
Treatment: drugs - Ibrutinib

Experimental: Arm A (Experimental Arm-BGB-3111) - Approximately 75 subjects with the MYD88 mutation will be enrolled in Cohort 1 and receive BGB-3111 in treatment [Arm A]

Active Comparator: Arm B (Active Comparator-Ibrutinib) - Approximately 75 subjects with the MYD88 mutation will be enrolled in Cohort 1 and receive Ibrutinib in treatment [Arm B]

Experimental: Arm C (Experimental Arm-BGB-3111) - Approximately 15-20 subjects found to have MYD88 wild type will be enrolled in Cohort 2 and receive BGB-3111 in treatment [Arm C]


Treatment: drugs: BGB-3111
160mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor

Treatment: drugs: Ibrutinib
420mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects achieving either a complete response (CR) or very good partial response (VGPR) in Cohort 1 using an adaptation of the response criteria updated at the Sixth IWWM as assessed by an independent review committee.</outcome>
      <timepoint>Up to 3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy measured by major response rate (MRR) in Cohort 1 - MRR defined as the proportion of subjects achieving a best response of response of CR, VGPR, or partial response (PR)</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy measured by duration of response (DOR) in Cohort 1 - DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy measured by progression-free survival (PFS) in Cohort 1 - PFS defined as time from randomization to the first documentation of progression or death, whichever occurs first</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resolution of treatment-precipitating symptoms in Cohort 1, measured by the absence of the symptoms that triggered initiation of study treatment (per the IWWM treatment guidelines) at any point during study treatment</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-lymphoma effect in Cohort 1, as measured by any reduction in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or hepatosplenomegaly</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety measured by the incidence, timing, and severity of treatment-emergent AEs in Cohort 1</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The incidence of AEs of Special Interest in Cohort 1</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Clinical and definitive histologic diagnosis of WM

          -  Measurable disease, requiring treatment

          -  Patients with no prior therapy for WM, must be considered inappropriate candidates for
             treatment with a standard chemoimmunotherapy regimen

          -  Age = 18 years old

          -  (ECOG) performance status of 0-2

          -  Adequate bone marrow function

          -  Adequate renal and hepatic function

          -  ECHO/MUGA demonstrating left ventricular ejection fraction (LVEF)= the lower limit of
             institutional normal

          -  Subjects may be enrolled who relapse after autologous stem cell transplant if they are
             at least 3 months after transplant, and after allogeneic transplant if they are at
             least 6 months post transplant.

          -  Females of childbearing potential must agree to use highly effective forms of birth
             control throughout the course of the study and at least up to 90 days after last dose
             of study drug. Males must have undergone sterilization- vasectomy, or utilize a
             barrier method

          -  Life expectancy of &gt; 4 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior exposure to a BTK inhibitor

          -  Evidence of disease transformation at the time of study entry

          -  Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy given
             with antineoplastic intent, targeted therapy, or radiation therapy within 3 weeks, or
             antibody-based therapy within 4 weeks of the start of study drug

          -  Major surgery within 4 weeks of study treatment

          -  Toxicity of = Grade 2 from prior anticancer therapy

          -  History of other active malignancies within 2 years of study entry, with exception of
             (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or
             squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally
             with curative intent

          -  Currently active, clinically significant cardiovascular disease such as uncontrolled
             arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease within 6 months
             of screening

          -  QTcF prolongation (defined as a QTcF &gt; 450 msec)

          -  Active, clinically significant Electrocardiogram (ECG) abnormalities

          -  Unable to swallow capsules or disease significantly affecting gastrointestinal
             function such as malabsorption syndrome, resection of the stomach or small bowel,
             symptomatic inflammatory bowel disease, or partial or complete bowel obstruction

          -  Uncontrolled active systemic infection or recent infection requiring parenteral
             anti-microbial therapy

          -  Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C

          -  Pregnant or lactating women

          -  Any life-threatening illness, medical condition, organ system dysfunction, need for
             profound anticoagulation, or bleeding disorder, which, in the investigator's opinion,
             could compromise the subject's safety

          -  Any medications which are strong or moderate cytochrome P450, family 3, subfamily A
             (CYP3A) inhibitors or strong CYP3A inducers</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>25/01/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>167</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Canberra Hospital - Garran</hospital>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Peninsula Health - Frankston</hospital>
    <hospital>Barwon Health, University Hospital Geelong - Geelong</hospital>
    <hospital>St. Vincent's Hospital - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3065 - Melbourne</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Oost-Vlaanderen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brugge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Králové</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre-Bénite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sigmaringen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Attiki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Novara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ravenna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Brzozów</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzów</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdynia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Opole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coruña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bournemouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Headington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newport</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BeiGene</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 vs ibrutinib
      in subjects with MYD88 Mutation Waldenström's Macroglobulinemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03053440</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Jane Huang, MD</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@beigene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>